Skip to main content
      RT @Yuz6Yusof: #POS0114 #EULAR2022 Can we identify #lupus patients better in electronic health records? Barbero et al. u

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 5 months ago
      #POS0114 #EULAR2022 Can we identify #lupus patients better in electronic health records? Barbero et al. used machine learning and developed a model to distinguish SLE diagnosis vs "near-misses". AUC: 0.90. Further validation can help future epidemiological studies @RheumNow https://t.co/vpLH8SWlWm
      RT @synovialjoints: Upadacitinib shows promising response in the treatment of nr-AxSpA in the SELECT-AXIS 2 study. Deodh

      Dr. Antoni Chan synovialjoints

      2 years 5 months ago
      Upadacitinib shows promising response in the treatment of nr-AxSpA in the SELECT-AXIS 2 study. Deodhar et al showed the ASAS40 response rate for UPA was twice vs placebo (45% vs 23%). 12/14 of the secondary endpoints were also met #EULAR2022 @RheumNow OP0016 https://t.co/dOWVJdLRtG
      RT @KDAO2011: Updated #EULAR2022 AxSpa Recc: The Algorithm @rheumnow https://t.co/fu46QJ3jmQ

      TheDaoIndex KDAO2011

      2 years 5 months ago
      Updated #EULAR2022 AxSpa Recc: The Algorithm @rheumnow https://t.co/fu46QJ3jmQ
      RT @Janetbirdope: ANCA vasculitis guidelines make sense. Less use of cyclophosphamide was already the case, rituximab ca

      Janet Pope Janetbirdope

      2 years 5 months ago
      ANCA vasculitis guidelines make sense. Less use of cyclophosphamide was already the case, rituximab can be for induction & maintenance, I am reluctant though in severe disease to stop maintenance Rx at 1 or 2 yrs and go longer as at least 1/3 will relapse beyond 2 yrs. @RheumNow https://t.co/3xRHWya2Uq
      RT @Janetbirdope: Occupational and non occupational silica exposure in RA increases ILD. At home exposure was higher in

      Janet Pope Janetbirdope

      2 years 5 months ago
      Occupational and non occupational silica exposure in RA increases ILD. At home exposure was higher in women due to cleaning - talc, laundry detergents, etc. Maybe some items should be banned or people protected - ? Masks. V interesting #OP0006 @RheumNow #EULAR2022 @eular_org
      RT @synovialjoints: Kading et al reports axial disease in 1/3 of patients with PsA, 55% females, 45% HLA-B27+, in 20% th

      Dr. Antoni Chan synovialjoints

      2 years 5 months ago
      Kading et al reports axial disease in 1/3 of patients with PsA, 55% females, 45% HLA-B27+, in 20% there was spinal but no SI joint involvement. Starts to define the Axial PsA patient as more female, less HLA-B27+ and may have only spinal inflammation #EULAR2022 @RheumNow OP0026
      RT @RichardPAConway: Botson et al. 152 patient RCT. MTX combo with pegloticase (to decrease antidrug abs). 6-month respo

      Richard Conway RichardPAConway

      2 years 5 months ago
      Botson et al. 152 patient RCT. MTX combo with pegloticase (to decrease antidrug abs). 6-month response (sUA<6 mg/dL) 71% vs 39%. Infusion reactions 3% vs 31%. @RheumNow #EULAR2022 OP0171 https://t.co/N29kYT3xkR https://t.co/Z4dUMD4Tt3
      RT @KDAO2011: GR2 cohort prospective study of pregnancies in 126 pts w/ SpA over 15 years
      -Rx exposure 23% steroids, 11%

      TheDaoIndex KDAO2011

      2 years 5 months ago
      GR2 cohort prospective study of pregnancies in 126 pts w/ SpA over 15 years -Rx exposure 23% steroids, 11% NSAIDS, 55% biologics - 116 live births, 7 miscarriages, 3 stillbirths - 36.5% had unfavorable pregnancy outcomes - 19% SGA - 4.8% preterm birth #EULAR2022 @rheumnow POS1000
      Are TYK2 inhibitors JAK inhibitors? Are they effective in PsA? Are they safer than JAKi? Read on to learn more.
      One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. Furthermore, the question of the utility of JAK inhibitors for the treatment of axial spondyloarthritis has been on the rise.